Catalyst

Slingshot members are tracking this event:

U.S. FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD

100%

Additional Information

Additional Relevant Details “Hepatitis C-infected patients who have decompensated cirrhosis and those who have previously received a liver transplant have an urgent need for treatment, but historically their options have been limited,” said Norbert Bischofberger, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer at Gilead. “We are pleased that health care providers now have the information needed to offer these patients an all-oral, 12-week duration therapy with high cure rates and a tolerable side effect profile.”
http://www.gilead.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Harvoni, Chronic Hepatits C, Liver Disease, Chronic Hepatitis C Virus, Liver Transplant, Ledipasvir, Sofosbuvir, Chronic Hepatitis C